Avalyn Pharma

company

About

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$35.50M
Industries
Biopharma,Biotechnology,Medical,Pharmaceutical
Founded date
Jan 1, 2011
Number Of Employee
1 - 10
Operating Status
Active

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics.

Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$35.50M
Avalyn Pharma has raised a total of $35.50M in funding over 2 rounds. Their latest funding was raised on Apr 27, 2020 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 27, 2020 Series B $35.50M 1 Norwest Venture Partners Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Avalyn Pharma is funded by 1 investors. Norwest Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Norwest Venture Partners Yes Series B